Title: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Candidate: MB-101 (IL13Rα2-specific CAR-T cells)
Status: Recruiting
Study ID #: NCT04661384
Title: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Candidate: MB-101 (IL13Rα2-specific CAR)
Status: Recruiting
Study ID #: NCT02208362
Title: IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma
Candidate: MB-101 (IL13Rα2-specific CAR)
Status: Recruiting
Study ID #: NCT04003649
Title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Candidate: MB-106 (CD20 CAR)
Status: Recruiting
Study ID #: NCT03277729
Title: Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)
Candidate: MB-108 (Oncolytic Virus)
Status: Recruiting
Study ID #: NCT03657576
For more information on our trials, visit www.clinicaltrials.gov.